Nike Stock Analysis 2026: Is NKE Bottoming Out or Falling Further? (March Earnings update!)
PT6M36S
PT6M36S
PT7M42S
PT8M27S
PT10M48S
PT8M4S
PT10M31S
PT7M19S
PT7M31S
PT6M16S
PT7M24S
PT8M38S
PT6M48S
PT7M42S
PT7M3S
PT7M12S
PT7M39S
PT8M26S
PT8M
PT8M
PT7M33S
PT7M13S
PT8M38S
PT8M7S
PT7M21S
PT7M55S
PT6M34S
PT9M2S
PT7M22S
PT8M5S
PT8M12S
PT6M41S
PT8M16SDave breaks down Space Mobile (ASTS) by exploring its cutting‑edge satellite broadband technology, recent contracts with Verizon and STC, and three valuation scenarios that range from a bearish $8 per share to a moonshot $900, emphasizing key technical resistance at $108 and support levels at $94, $95, and $80. He concludes the stock is a high‑risk, high‑reward play, advising viewers to watch for a decisive $108 breakout or a bounce off support before considering any speculative entry, and reminds them to like, subscribe, and consult a qualified financial professional.
PT7M19SDave breaks down Bank of America's Q4 2025 earnings beat, emphasizing robust net interest income, AI‑driven operating leverage, and management’s upbeat 2026 guidance, while explaining why the stock retreated amid investment‑banking weakness, regulatory worries, and Fed uncertainty. He then outlines three scenarios—a base case valuing BAC around $59, a bull case near $68, and a bare case near $48—suggesting a cautious long‑term buy near the $52 support level but warning of potential downside risks.
PT6M53SIn this video, Dave breaks down Visa’s (V) near‑term outlook amid President Trump’s proposed 10% cap on credit‑card interest rates, detailing three probability‑weighted scenarios—a base case at ~$33.33, a bullish case at ~$40, and a bearish “bare” case at $265—with technical analysis highlighting key support levels around $325‑$300. He concludes that, given the regulatory headwinds and weak technicals, investors should stay cautious and consider buying only near the lower support zones rather than assuming a bottom has been reached.
PT8M13S. Good.Dave breaks down Capital One (COF) after its Discover acquisition, weighing bullish analyst upgrades and $1.5 bn in synergies against President Trump's proposed 10% cap on one‑year credit‑card rates that could squeeze margins. Using base, bull and bear case models, he derives a weighted fair value of $31.92—far below the current $249 price—and argues the stock is a buy if it can break the $260 resistance, with support levels at $228, $207 and $180 offering entry points.
PT8M50S.In this January 2026 update, Dave breaks down SanDisk’s (SNDK) 127% 90‑day rally, detailing how AI‑driven NAND shortages and the company’s Bix‑8 technology are fueling aggressive revenue forecasts that could push the fair‑value target to $376 in a base case or $550 in a bull case. He concludes the stock is currently bullish, having just broken above $345, but reminds viewers that the analysis is for informational purposes only and not financial advice.
PT8M.In this video, Dave breaks down Chevron’s (CVX) current market narrative, weighing the bullish geopolitical upside from potential Venezuelan oil access against earnings concerns and oil‑price volatility through three weighted scenarios and key technical levels. He concludes that CVX is a hold with notable upside if the Venezuelan catalyst materializes, while also highlighting support zones that could offer buying opportunities if the stock slides.
PT8M3S.In this episode the host breaks down Exxon Mobil (XOM), highlighting its recent 2.7% monthly gain, strong refining margins, upcoming earnings with projected EPS decline, and the impact of geopolitical factors like Venezuela, while walking through three valuation scenarios—a 50%‑probability base case valuing the stock at $128, a 35% bull case up to $142, and a 15% bear case near $93. He concludes that XOM remains a buy at current levels around $122‑$123, suggesting layering positions near support zones while noting the usual disclaimer that the analysis is for educational purposes and not personal financial advice.
PT7M20SIn this video, we analyze the complexities surrounding Novon Nordisk (NVO) as it navigates the excitement of FDA approval for its oral GLP-1 pill, Wegovy, against a backdrop of profit warnings and operational challenges. We break down potential market scenarios—bullish, bearish, and base cases—to help investors understand their options before making decisions regarding this volatile stock.
PT8M5SIn this video, Dave provides an in-depth analysis of United Health Group (UNH), highlighting the current mixed market sentiment and the external pressures impacting the stock. With projections for 2026 earnings growth juxtaposed against regulatory risks, he presents three potential scenarios for UNH's future, emphasizing the importance of technical levels for investors to watch.